Florfenikol Vetos-Farma pharmacology
The pharmacokinetic disposition of Florfenikol Vetos-Farma™ was evaluated in feeder calves following a single subcutaneous injection at a dose rate of 40 mg Florfenikol Vetos-Farma/kg body weight. Administration of Florfenikol Vetos-Farma™ resulted in Florfenikol Vetos-Farma plasma concentrations of 2 µg (mcg)/mL within two hours of injection.
Cmax (µg/mL) | Tmax (hr) | AUClast (µg*hr/mL) | T½ (hr) | |
---|---|---|---|---|
Cmax: Maximum observed plasma concentration Tmax: Time at which Cmax was observed AUClast: Area under the plasma-concentration-time curve from time zero to the last quantifiable concentration that is equal to or greater than the limit of quantification of the validated analytical method T½: Terminal elimination half-life % CV: Percent coefficient of variance | ||||
| ||||
n | 24 | 24 | 24 | 23* |
Mean | 5.93 | 5† | 150 | 37.7 |
% CV | 38.3 | 2-12† | 20.9 | 27.3 |
Figure 1. Mean Florfenikol Vetos-Farma Plasma Concentration versus Time Following a Single Subcutaneous Injection of Florfenikol Vetos-Farma™ at a Dose Rate of 40 mg Florfenico/kg Body Weight in Feeder Calves (Mean ± Standard Error of the Mean) |
MICROBIOLOGY
Florfenikol Vetos-Farma is a synthetic, broad-spectrum antibiotic active against many Gram-negative and Gram-positive bacteria isolated from domestic animals. It acts by binding to the 50S ribosomal subunit and inhibiting bacterial protein synthesis. Florfenikol Vetos-Farma is generally considered a bacteriostatic drug, but it exhibits bactericidal activity against certain bacterial species. In vitro studies demonstrate that Florfenikol Vetos-Farma is active against the BRD pathogens M. haemolytica, P. multocida, H. somni, and M. bovis and that Florfenikol Vetos-Farma exhibits bactericidal activity against strains of M. haemolytica and H. somni.
The minimum inhibitory concentrations (MICs) of Florfenikol Vetos-Farma were determined for BRD isolates obtained from calves enrolled in BRD field studies in the U.S. in 2006 using methods recommended by the Clinical and Laboratory Standards Institute (M31-A2). Isolates were obtained from pre-treatment nasal swabs from all calves enrolled at all four sites, post-treatment nasal swabs from treatment failures in the Florfenikol Vetos-Farma Injectable Solution and saline control treatment groups at three sites, and lung tissue from one calf that died in the saline control treatment group. The results are shown below in Table 2.
Indicated pathogens | Year of isolation | No. of isolates | MIC50† (µg/mL) | MIC90† (µg/mL) | MIC range (µg/mL) |
---|---|---|---|---|---|
| |||||
Mannheimia haemolytica | 2006 | 158 | 1.0 | 1.0 | 0.5 to 32 |
Pasteurella multocida | 2006 | 103 | 0.5 | 0.5 | ≤ 0.125 to 16 |
Histophilus somni | 2006 | 85 | ≤ 0.125 | ≤ 0.125 | ≤ 0.125 to 0.25 |
Reviews
The results of a survey conducted on ndrugs.com for Florfenikol Vetos-Farma are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Florfenikol Vetos-Farma. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported administration
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology